The Value of Magnetic Resonance in Differentiation between Brain Glioma and Treatment Induced Injury

Bieza, Anvita; Krumina, Gaida

doi:10.2478/v10163-012-0005-9

Abstract

Introduction. The further therapeutic management decisions in glioma patients after the radiation/chemotherapy may be difficult because the treatment induced brain injury can mimic tumor recurrence clinically and on neuroimaging.

Aim of the Study was to assess the usefulness of magnetic resonance spectroscopy (MRS) and diffusion tensor imaging (DTI) in differentiation between glial tumor recurrence and radiation/chemotherapy-induced changes in the brain.

Material and methods. 73 patients with primary brain gliomas and 77 gliomas patients after combined therapy with possibly treatment induced changes underwent MRS and DTI. Fractional anisotropy (FA) and metabolite ratios were measured in the tumor and pathological signal intensity area adjacent to post-surgical cavity.

Results. Mean choline/creatine (Cho/Cr), myoinositol/creatine (MI/Cr), lactate-lipid/creatine (LL/Cr) ratios of brain gliomas was statistically significant higher and FA values lower than those in the pathological signal intensity area adjacent to post-surgical cavity. No differences were found in mean N-acetyl aspartate/creatine (NAA/Cr) ratios among two groups.

Conclusions. Our study suggests that Cho/Cr, MI/Cr, LL/Cr and FA measures should be recommended as additional highly informative tool to conventional structural magnetic resonance imaging (MRI) when monitoring gliomas patients after combined therapy.

References

1. Bonicelli C, Bacci A, Agat i R, Leonardi M. Potential of high field functional MRI in the neuroradiological diagnosis of brain tumours // The Neuroradiol J, 2009; 22:534-545
Search in Google Scholar
2. Brandsma D, Stalpers L, Taal W, Sminia P, Bent MJ. Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas // Lancet Oncol, 2008; 9:453-461
Search in Google Scholar
3. Chaskis C, Neyns B, Michot te A, Ridder M, Everaert H. Pseudoprogression after radiotherapy with concurrent temozolomide for high-grade glioma: clinical observations and working recommendations // Surg Neurol, 2009; 72:423-428
Search in Google Scholar
4. Costanzo AD, Scarabino T, Trojsi F, Popolizio T, Catapano D, Giannatempo GM, Bonavita S, Portaluri M, Tosetti M, Angelo VA, Salvolini U, Tedeschi G. Proton MR spectroscopy of cerebral gliomas at 3T: spatial heterogeneity, and tumour grade and extent // Eur Radiol, 2008; 18:1727-1735
Search in Google Scholar
5. Dincer A, Isik U, Kosak E, Ozet M. Extrapontine myelinolysis in a child: a rare case with MRI, DWI and MRS follow-up // The Neuroradiology Journal, 2008; 21:527-537
Search in Google Scholar
6. Gerstner L, Jellinger K, H eiss WD, Wober G. Morphological changes in anaplastic gliomas treated with radiation and chemotherapy // Acta Neurochir, 1977; 36:117-138
Search in Google Scholar
7. Goebell E, Fiehler J, Ding XQ, Paustenbach S, Nietz S, Heese O, Kucinski T, Hagel C, Westphal M, Zeumer H. Disarrangement of fiber tracts and decline of neuronal density correlate in glioma patients - a combined diffusion tensor imaging and 1H-MR spectroscopy study // Am J Neuroradiol, 2006; 27:1427-1431
Search in Google Scholar
8. Huang J, Wang AM, Shetty A , Maitz AH, Yan D, Doyle D, Richey K, Park S, Pieper DR, Chen PY, Grills IS. Differentiation between intra-axial metastatic tumor progression and radiation injury following fractionated radiation therapy or stereotactic radiosurgery using MR spectroscopy, perfusion MR imaging or volume progression modeling // Magn Reson Imaging, 2011; 29:993-1001
Search in Google Scholar
9. Hygino CJLC, Rodriguez I, Domingues RC, Gasparetto EL, Sorensen AG. Pseudoprogression and pseudoresponse: imaging challenges in the assessment of posttreatment glioma // Am J Neuroradiol, 2011; 32:1978-1985
Search in Google Scholar
10. Kallenberg K, Bock H, Helm s G, Jung K, Wrede A, Buhk JH, Giese A, Frahm J, Strik H, Dechent P, Knauth M. Untreated glioblastoma multiforme: increased myo-inositol and glutamine levels in the contralateral cerebral hemisphere at proton MR spectroscopy // Radiology, 2009; 253:805-812
Search in Google Scholar
11. Louis DN, Ohgaki H, Wiestl er OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P: The 2007 WHO classification of tumours of the central nervous system // Acta Neuropathol, 2007; 114:97-109 10.1007/s00401-007-0243-4192916517618441
Search in Google Scholar
12. Nakajima T, Kumabe T, Kana mori M, Saito R, Tashiro M, Watanabe M, Tominaga T: Differential diagnosis between radiation necrosis and glioma progression using sequential proton magnetic resonance spectroscopy and methionine positron emission tomography // Neurol Med Chir, 2009 49:394-401 10.2176/nmc.49.39419779283
Search in Google Scholar
13. Nelson SJ. Assessment of t herapeutic response and treatment planning for brain tumors using metabolic and physiological MRI // NMR Biomed, 2011; 24:734-749
Search in Google Scholar
14. Oshiro S, Tsugu H, Komatsu F, Abe H, Onishi H, Ohmura T, Iwaasa M, Sakamoto S, Fukushima T. Quantitative assessment of gliomas by proton magnetic resonance spectroscopy // Anticancer Res, 2007; 27:3757-3764
Search in Google Scholar
15. Pope WB, Young JR, Ellings on BM. Advances in MRI assessment of gliomas and response to anti- VEGF therapy // Curr Neurol Neurosci Rep, 2011; 11:336-344
Search in Google Scholar
16. Principi M, Italiani M, Ot taviano P. Perfusion MRI in the evaluation of cerebral blood volume and mean transit time in untreated and recurrent glioblastomas // The Neuroradiology Journal, 2009 22:48-57 10.1177/19714009090220010824206953
Search in Google Scholar
17. Schillaci O, Travascio L, Bruni C, Bazzocchi G, Testa A, Garaci FG, Melis M, Floris R, Simonetti G. Molecular imaging and magnetic resonance imaging in early diagnosis of Alzheimer’s disease // The Neuroradiology Journal, 2008; 21:755-771
Search in Google Scholar
18. Smith EA, Carlos RC, Junck LR, Tsien CI, Elias A, Sundgren PC. Developing a clinical decision model: MR spectroscopy to differentiate between recurrent tumor and radiation change in patients with new contrast- enhancing lesions // Am J Roentgenol, 2009 192:45-52 10.2214/AJR.07.393419155380
Search in Google Scholar
19. Sundgren PC. MR spectrosco py in radiation injury // Am J Neuroradiol, 2009; 30:1469 -1476
Search in Google Scholar
20. Sundgren PC, Nagesh V, Eli as A, Tsien C, Junck L, Hassan GDM, Lawrence TS, Chenevert TL, Rogers L, McKeever P, Cao Y. Metabolic alterations: a biomarker for radiation-induced injury of normal brain. An MR spectroscopy study // J Magn Reson Imaging, 2009; 29:291-297 10.1002/jmri.21657267951819161192
Search in Google Scholar
21. Wang YX, King AD, Zhou H, Leung SF, Abrigo J, Chan YL, Hu CW, Yeung DK, Ahuja AT. Evolution of radiation-induced brain injury: MR imaging- based study // Radiology, 2010; 254:210-218
Search in Google Scholar
22. Weybright P, Sundgren PC, Maly P, Hassan DG, Nan B, Rohrer S, Junck L. Differentiation between brain tumor recurrence and radiation injury using MR spectroscopy // Am J Roentgenol, 2005; 185:1471- 1476
Search in Google Scholar
23. Yaman E, Buyukberber S, Be nekli M, Oner Y, Ugur Coskun U, Akmansu M, Ozturk B, Kaya AO, Uncu D, Yildiz R. Radiation induced early necrosis in patients with malignant gliomas receiving temozolomide // Clin Neurol Neurosur, 2010; 112:662-667
Search in Google Scholar
24. Yerli H, Ağıldere AM, Özen O, Geyik E, Atalay B, Elhan AH. Evaluation of cerebral glioma grade by using normal side creatine as an internal reference in multi-voxel 1H-MR spectroscopy // Diagn Interv Radiol, 2007; 13:3-9
Search in Google Scholar

The Value of Magnetic Resonance in Differentiation between Brain Glioma and Treatment Induced Injury

Abstract

Paradigm

My account